A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Insulin With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-254)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 467 participants.
Also called NCT01590797
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 467 participants
- Sponsor
- Registry
-
NCT01590797
-
- Other papers using this trial's data
- Sitagliptin added to stable insulin therapy with or without metformin in Chinese patients with type 2 diabetes
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Not reported
- Registry status
- Completed
Technical summary
Registry record NCT01590797. Randomized; triple masking; primary purpose treatment. Start 2012-07-10 (actual); primary completion 2014-06-11 (actual). Results posted on 2015-01-27.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Insulin With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-254)
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Sitagliptin
- Intervention (Drug)
- Placebo
- Intervention (Biological)
- Insulin
- Intervention (Drug)
- Metformin
- Lead sponsor
- Merck Sharp & Dohme LLC
Record details
- Record id
cardio:ct-nct01590797- Content hash
56438dc20607370532e5f54473785cb2a49e37a039d975aa8a6ac66ed95549f9